Message from the TROG President
Associate Professor Farshad Foroudi
TROG Cancer Research is Australia and New Zealand’s premier collaborative cancer trials group that conducts research involving radiotherapy. Over the past 29 years it has gained national and international recognition in trial excellence, having accrued more than 14,500 patients to its studies. TROG was recognised for its role in cancer research winning the NSW Premier’s award for “Innovation in Cancer Clinical Trials” in 2013.
1 in 2 people in Australia will be diagnosed with cancer in their lifetime and more than 50 per cent of these will be treated with radiotherapy. Radiotherapy is used widely to treat cancers including breast, skin, prostate, lung, brain, bladder and gastrointestinal amongst others.
Our organisation, consisting of more than 1400 members, is made up of an extensive network of oncologists, radiation therapists, physicists, data managers and other researchers conducting research across a range of cancers. TROG is committed to promoting quality cancer research, addressing important scientific questions and facilitating ease of trial participation. TROG Cancer Research has completed in excess of 100 cancer clinical trials and from this research have had more than 170 publications.
TROG Cancer Research is a not-for-profit company limited by guarantee. TROG is actively engaged, and collaborates, with other national and overseas Co-operative Trials Groups, the Clinical Oncology Society of Australia, Cancer Australia, Cancer Institute NSW, the Faculty of Radiation Oncology and Cancer Consumer Groups.
Our website is intended as a useful resource for patients, families, carers, the community, our membership, corporate partners and donors. To learn more about how our research is improving treatments for patients you will find videos from past participants, details of our current research program, outcomes from our completed trials, information explaining what radiotherapy and cancer research trials are with links to other useful information.
If you have any questions, please don't hesitate to contact us. In the meantime, we thank you for visiting and therefore supporting our vital work in the treatment of cancer patients.